Research Analysts’ Recent Ratings Changes for Audentes Therapeutics (BOLD)

A number of firms have modified their ratings and price targets on shares of Audentes Therapeutics (NASDAQ: BOLD) recently:

  • 1/11/2018 – Audentes Therapeutics was given a new $37.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/5/2018 – Audentes Therapeutics was given a new $44.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 1/5/2018 – Audentes Therapeutics had its “buy” rating reaffirmed by analysts at William Blair.
  • 1/4/2018 – Audentes Therapeutics had its “hold” rating reaffirmed by analysts at Raymond James Financial, Inc..
  • 1/4/2018 – Audentes Therapeutics had its price target raised by analysts at Wedbush to $56.00. They now have an “outperform” rating on the stock.
  • 1/4/2018 – Audentes Therapeutics was given a new $37.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 12/20/2017 – Audentes Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $37.00 price target on the stock.
  • 12/20/2017 – Audentes Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 12/6/2017 – Audentes Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 12/5/2017 – Audentes Therapeutics is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $35.00 price target on the stock.
  • 12/1/2017 – Audentes Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.

Audentes Therapeutics Inc (BOLD) traded down $0.14 during trading on Friday, hitting $37.86. The stock had a trading volume of 338,730 shares, compared to its average volume of 596,285. Audentes Therapeutics Inc has a twelve month low of $13.90 and a twelve month high of $41.80. The stock has a market capitalization of $1,125.85, a PE ratio of -10.85 and a beta of -0.21.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.88). equities analysts anticipate that Audentes Therapeutics Inc will post -3.5 earnings per share for the current fiscal year.

In other news, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $26.84, for a total transaction of $268,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $28.53, for a total value of $228,240.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock valued at $1,052,480 in the last 90 days. Company insiders own 47.30% of the company’s stock.

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply